featured
2017 Top Stories in Cardiology: The Inflammation Hypothesis of Atherosclerosis Comes of Age: The CANTOS Trial
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Interleukin 1 Beta as a Target for Atherosclerosis Therapy
- Participatory Role of Inflammation in Atherosclerotic Disease Confirmed by CANTOS
- Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis
- Relationship of C-Reactive Protein Reduction to Cardiovascular Event Reduction Following Treatment With Canakinumab
- Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017;70(18):2278-2289.
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131.
- Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833-1842.
- Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial [published online November 13, 2017]. Lancet. DOI: http://dx.doi.org/10.1016/S0140-6736(17)32814-3.
Disclosure statements are available on the authors' profiles: